AstraZeneca and Merck announced that the Japanese Ministry of Health, Labour and Welfare approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy.

Cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival at the planned second interim analysis for the population of second-line and third-line patients enrolled in the CELESTIAL study.

Trisenox (arsenic trioxide) injection was approved in combination with tretinoin for treating adults with newly diagnosed low-risk acute promyelocytic leukemia.

The European Commission granted Marketing Authorization for Shire’s ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated], for on-demand and prophylactic use in patients 12 years and older living with hemophilia A.

Mr. du Toit is responsible for leading Publicis Health’s global business development strategy.

Outcome Health, which provides health education at the moment of care to improve patient outcomes, announced that Vince Panozzo was promoted to Executive Vice President of Sales.

McCann Health announced the appointment of Marcus Sigurdsson to the new position of Global Chief Digital Officer.

Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.

Vertex Pharmaceuticals Incorporated announced that the European Commission granted extension of the Marketing Authorization for Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, to include children ages 6 through 11.

Celgene Corporation will acquire Impact Biomedicines – which is developing fedratinib for myelofibrosis and polycythemia vera – for $1.1 billion upfront.